{"paper_id":"f87f9d65-6dfd-4359-9924-2ec76c927cbf","body_text":"Abstract\nPurpose\nTo investigate whether postoperative GnRH agonist (GnRH-a) treatment can prevent endometriosis recurrence.\nMethods\nThis meta-analysis searched PubMed, Embase and Cochrane Library for relevant studies published online before June 2015. Seven randomized controlled trials including 328 patients with postoperative GnRH-a treatment and 394 patients in control group were included in the meta-analysis. In the meta-analysis, the recurrence rate of GnRH-a group compared with control group was evaluated with odds ratio (OR) and its 95 % confidence interval (CI). Heterogeneity, small study effect and publication bias were, respectively, assessed using Higgins I 2, sensitivity analysis and funnel plot.\nResults\nPostoperative GnRH-a treatment for endometriosis (pooled OR = 0.71; 95 % CI 0.52–0.96) was superior to expectant or placebo treatment in prevention of the recurrence. The recurrence rate decreased significantly in patients who received 6 months GnRH-a treatment (pooled OR = 0.59, 95 % CI 0.38–0.90), whereas no significant difference of recurrence rate existed between patients with 3 months post-surgical GnRH-a therapy and the control group (pooled OR = 0.87, 95 % CI 0.56–1.34). No significant heterogeneity and small study effect were found in the meta-analysis. However, publication bias did existed in the present meta-analysis.\nConclusions\nLonger-term (6 months) postoperative administration of GnRH-a can decrease the recurrence risk of endometriosis, whereas 3 months duration of GnRH-a therapy makes no significant difference in preventing the recurrence of endometriosis. Therefore, instead of a 3 month therapy, the duration of the postoperative administration should be longer enough (6 months) to prevent the recurrence of endometriosis.\nSimilar content being viewed by others\nReferences\nEskenazi B, Warner ML (1997) Epidemiology of endometriosis. Obstet Gynecol Clin North Am 24(2):235–258\nDunselman GAJ, Vermeulen N, Becker C, Calhaz-Jorge C, D’Hooghe T, De Bie B, Heikinheimo O, Horne AW, Kiesel L, Nap A, Prentice A, Saridogan E, Soriano D, Nelen W (2014) ESHRE guideline: management of women with endometriosis. Hum Reprod 29(3):400–412. doi:10.1093/humrep/det457\nFedele L, Bianchi S, Zanconato G, Berlanda N, Raffaelli R, Fontana E (2006) Laparoscopic excision of recurrent endometriomas: long-term outcome and comparison with primary surgery. Fertil Steril 85(3):694–699. doi:10.1016/j.fertnstert.2005.08.028\nWheeler JM, Malinak LR (1983) Recurrent endometriosis: incidence, management, and prognosis. Am J Obstet Gynecol 146(3):247–253\nFedele L, Bianchi S, Di Nola G, Candiani M, Busacca M, Vignali M (1994) The recurrence of endometriosis. Ann N Y Acad Sci 734:358–364\nWeir E, Mustard C, Cohen M, Kung R (2005) Endometriosis: what is the risk of hospital admission, readmission, and major surgical intervention? J Minim Invasive Gynecol 12(6):486–493. doi:10.1016/j.jmig.2005.09.001\nCheong Y, Tay P, Luk F, Gan HC, Li TC, Cooke I (2008) Laparoscopic surgery for endometriosis: How often do we need to re-operate? J Obstet Gynaecol 28(1):82–85. doi:10.1080/01443610701811761\nKennedy S (2005) ESHRE guideline for the diagnosis and treatment of endometriosis. Hum Reprod 20(10):2698–2704. doi:10.1093/humrep/dei135\nJee BC, Lee JY, Suh CS, Kim SH, Choi YM, Moon SY (2009) Impact of GnRH agonist treatment on recurrence of ovarian endometriomas after conservative laparoscopic surgery. Fertil Steril 91(1):40–45\nVercellini P, Crosignani PG, Fadini R, Radici E, Belloni C, Sismondi P (1999) A gonadotrophin-releasing hormone agonist compared with expectant management after conservative surgery for symptomatic endometriosis. Br J Obstet Gynaecol 106(7):672–677\nHornstein MD, Hemmings R, Yuzpe AA, Heinrichs WL (1997) Use of nafarelin versus placebo after reductive laparoscopic surgery for endometriosis. Fertil Steril 5:860–864\nParazzini F, Fedele L, Busacca M, Falsetti L, Pellegrini S, Venturini PL, Stella M (1994) Postsurgical medical treatment of advanced endometriosis: results of a randomized clinical trial. Am J Obstet Gynecol 171(5):1205–1207\nBusacca M, Somigliana E, Bianchi S, De Marinis S, Calia C, Candiani M, Vignali M (2001) Post-operative GnRH analogue treatment after conservative surgery for symptomatic endometriosis stage III-IV: a randomized controlled trial. Hum Reprod 16(11):2399–2402\nLoverro G, Carriero C, Rossi AC, Putignano G, Nicolardi V, Selvaggi L (2008) A randomized study comparing triptorelin or expectant management following conservative laparoscopic surgery for symptomatic stage III-IV endometriosis. Eur J Obstet Gynecol Reprod Biol 136(2):194–198\nAlborzi S, Hamedi B, Omidvar A, Dehbashi S, Alborzi M (2011) A comparison of the effect of short-term aromatase inhibitor (letrozole) and GnRH agonist (triptorelin) versus case control on pregnancy rate and symptom and sign recurrence after laparoscopic treatment of endometriosis. Arch Gynecol Obstet 284(1):105–110\nJadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17(1):1–12\nHiggins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. Bmj 327(7414):557–560. doi:10.1136/bmj.327.7414.557\nSesti F, Capozzolo T, Pietropolli A, Marziali M, Bollea MR, Piccione E (2009) Recurrence rate of endometrioma after laparoscopic cystectomy: a comparative randomized trial between post-operative hormonal suppression treatment or dietary therapy vs. placebo. Eur J Obstet Gynecol Reprod Biol 147(1):72–77\nAcién P, Quereda F, Campos A, Gomez-Torres MJ, Velasco I, Gutierrez M (2002) Use of intraperitoneal interferon alpha-2b therapy after conservative surgery for endometriosis and postoperative medical treatment with depot gonadotropin-releasing hormone analog: a randomized clinical trial. Fertil Steril 4:705–711\nLiu X, Yuan L, Shen F, Zhu Z, Jiang H, Guo SW (2007) Patterns of and risk factors for recurrence in women with ovarian endometriomas. Obstet Gynecol 109(6):1411–1420. doi:10.1097/01.AOG.0000265215.87717.8b\nRegidor PA, Regidor M, Kato K, Bier UW, Buhler K, Schindler AE (1997) Long-term follow-up on the treatment of endometriosis with the GnRH- agonist buserelinacetate. Long-term follow-up data (up to 98 months) of 42 patients with endometriosis who were treated with GnRH-agonist buserelinacetate (Suprecur(registered trademark)), were evaluated in respect of recurrence of pain symptoms and pregnancy outcome. Eur J Obstet Gynecol Reprod Biol 73(2):153–160\nSesti F, Pietropolli A, Capozzolo T, Broccoli P, Pierangeli S, Bollea MR, Piccione E (2007) Hormonal suppression treatment or dietary therapy versus placebo in the control of painful symptoms after conservative surgery for endometriosis stage III-IV. A randomized comparative trial. Fertil Steril 88(6):1541–1547\nMettler L, Ruprai R, Alkatout I (2014) Impact of medical and surgical treatment of endometriosis on the cure of endometriosis and pain. Biomed Res Int 2014:264653. doi:10.1155/2014/264653\nYap C, Furness S, Farquhar C (2004) Pre and post operative medical therapy for endometriosis surgery. Cochrane Database Syst Rev (3):CD003678. doi:10.1002/14651858.CD003678.pub2\nVercellini P, Frontino G, De Giorgi O, Pietropaolo G, Pasin R, Crosignani PG (2003) Endometriosis: preoperative and postoperative medical treatment. Obstet Gynecol Clin North Am 30(1):163–180\nFerrero S, Abbamonte LH, Parisi M, Ragni N, Remorgida V (2007) Dyspareunia and quality of sex life after laparoscopic excision of endometriosis and postoperative administration of triptorelin. Fertil Steril 87(1):227–229. doi:10.1016/j.fertnstert.2006.06.018\nHornstein MD, Yuzpe AA, Burry KA, Heinrichs LR, Buttram VL Jr, Orwoll ES (1995) Prospective randomized double-blind trial of 3 versus 6 months of nafarelin therapy for endometriosis associated pelvic pain. Fertil Steril 63(5):955–962\nOlive DL (2004) Optimizing gonadotropin-releasing hormone agonist therapy in women with endometriosis. Treat Endocrinol 3(2):83–89\nSagsveen M, Farmer JE, Prentice A, Breeze A (2003) Gonadotrophin-releasing hormone analogues for endometriosis: bone mineral density. Cochrane Database Syst Rev (4):CD001297. doi:10.1002/14651858.cd001297\nHowell R, Edmonds DK, Dowsett M, Crook D, Lees B, Stevenson JC (1995) Gonadotropin-releasing hormone analogue (goserelin) plus hormone replacement therapy for the treatment of endometriosis: a randomized controlled trial. Fertil Steril 64(3):474–481\nKikuchi I, Takeuchi H, Kitade M, Shimanuki H, Kumakiri J, Kinoshita K (2006) Recurrence rate of endometriomas following a laparoscopic cystectomy. Acta Obstet Gynecol Scand 85(9):1120–1124. doi:10.1080/00016340600627154\nAuthor information\nAuthors and Affiliations\nCorresponding author\nEthics declarations\nThis article does not contain any studies with human participants or animals performed by any of the authors.\nFunding\nThis study was supported by grants from the National Natural Science Foundation of China (81370696) as well as the Science and Technology Development planning of Shandong (2013GGE27031).\nConflict of interest\nThe authors declare that they have no conflict of interest.\nAdditional information\nQ. Zheng and H. Mao contributed equally.\nElectronic supplementary material\nBelow is the link to the electronic supplementary material.\nRights and permissions\nAbout this article\nCite this article\nZheng, Q., Mao, H., Xu, Y. et al. Can postoperative GnRH agonist treatment prevent endometriosis recurrence? A meta-analysis. Arch Gynecol Obstet 294, 201–207 (2016). https://doi.org/10.1007/s00404-016-4085-y\nReceived:\nAccepted:\nPublished:\nIssue date:\nDOI: https://doi.org/10.1007/s00404-016-4085-y","source_license":"CC0","license_restricted":false}